A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
Status:
Completed
Trial end date:
1998-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related
Kaposi's sarcoma. To determine the effects of IL-4 on tumor growth in patients with
AIDS-related Kaposi's sarcoma.
IL-4 exhibits a variety of beneficial effects on the immune system and is a potent inhibitor
of Kaposi's sarcoma cells in vitro.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)